{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:37:40Z","timestamp":1794839860947,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006012","name":"Christian Doppler Forschungsgesellschaft","doi-asserted-by":"publisher","award":["CD10277102"],"award-info":[{"award-number":["CD10277102"]}],"id":[{"id":"10.13039\/501100006012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006012","name":"Christian Doppler Forschungsgesellschaft","doi-asserted-by":"publisher","award":["CD10277102"],"award-info":[{"award-number":["CD10277102"]}],"id":[{"id":"10.13039\/501100006012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P32771"],"award-info":[{"award-number":["P32771"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>To validate the clinical utility of a previously identified circulating tumor DNA methylation marker (meth-ctDNA) panel for disease detection and survival outcomes, meth-ctDNA markers were compared to PSA levels and PSMA PET\/CT findings in men with different stages of prostate cancer (PCa).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>122 PCa patients who underwent [\u2076\u2078Ga]Ga-PSMA-11 PET\/CT and plasma sampling (03\/2019\u201308\/2021) were analyzed. cfDNA was extracted, and a panel of 8 individual meth-ctDNA markers was queried. PET scans were qualitatively and quantitatively assessed. PSA and meth-ctDNA markers were compared to PET findings, and their relative prognostic value was evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>PSA discriminated best between negative and tumor-indicative PET scans in all (AUC 0.77) and hormone-sensitive (hsPC) patients (0.737). In castration-resistant PCa (CRPC), the meth-ctDNA marker <jats:italic>KLF8<\/jats:italic> performed best (AUC 0.824). <jats:italic>CHST11<\/jats:italic> differentiated best between non- and metastatic scans (AUC 0.705) overall, <jats:italic>KLF8<\/jats:italic> best in hsPC and CRPC (AUC 0.662, 0.85). Several meth-ctDNA markers correlated low to moderate with the tumor volume in all (5\/8) and CRPC patients (6\/8), while PSA levels correlated moderately to strongly with the tumor volume in all groups (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). CRPC overall survival was independently associated with <jats:italic>LDAH<\/jats:italic> and PSA (<jats:italic>p<\/jats:italic>\u2009=\u20090.0168, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The studied meth-ctDNA markers are promising for the minimally-invasive detection and prognostication of CRPC but do not allow for clinical characterization of hsPC. Prospective studies are warranted for their use in therapy response and outcome prediction in CRPC and potential incremental value for PCa monitoring in PSA-low settings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13148-025-01811-5","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T14:42:11Z","timestamp":1740494531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Imaging and outcome correlates of ctDNA methylation markers in prostate cancer: a comparative, cross-sectional [\u2076\u2078Ga]Ga-PSMA-11 PET\/CT study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-7314","authenticated-orcid":false,"given":"Kilian","family":"Kluge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Lotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Einspieler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Haberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Spielvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Amereller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Grubm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Kenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"1811_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1811_CR2","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A. SEER cancer statistics review (CSR), 1975\u20132016. National Cancer Institute. Update April"},{"key":"1811_CR3","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119\u201334.","journal-title":"Ann Oncol"},{"key":"1811_CR4","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1101\/gad.315739.118","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang G, Zhao D, Spring DJ, Depinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018;32:1105\u201340.","journal-title":"Genes Dev"},{"key":"1811_CR5","doi-asserted-by":"publisher","first-page":"7225","DOI":"10.1038\/s41388-020-01496-5","volume":"39","author":"YA Wang","year":"2020","unstructured":"Wang YA, Sfakianos J, Tewari AK, Cordon-Cardo C, Kyprianou N. Molecular tracing of prostate cancer lethality. Oncogene. 2020;39:7225\u201338.","journal-title":"Oncogene"},{"key":"1811_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.04.004","author":"M Miszczyk","year":"2024","unstructured":"Miszczyk M, Rajwa P, Fazekas T, Briganti A, Karakiewicz PI, Roupr\u00eat M, et al. The state of intermediate clinical endpoints as surrogates for overall survival in prostate cancer in 2024. Eur Urol Oncol. 2024. https:\/\/doi.org\/10.1016\/j.euo.2024.04.004.","journal-title":"Eur Urol Oncol"},{"key":"1811_CR7","doi-asserted-by":"publisher","first-page":"k3519","DOI":"10.1136\/bmj.k3519","volume":"362","author":"D Ilic","year":"2018","unstructured":"Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519.","journal-title":"BMJ"},{"key":"1811_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/pcan.2016.71","volume":"20","author":"AH Bryce","year":"2017","unstructured":"Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 2017;20:221\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1811_CR9","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.eururo.2020.12.037","volume":"79","author":"I Casanova-Salas","year":"2021","unstructured":"Casanova-Salas I, Athie A, Boutros PC, Del Re M, Miyamoto DT, Pienta KJ, et al. Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer. Eur Urol. 2021;79:762\u201371.","journal-title":"Eur Urol"},{"key":"1811_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","volume":"563","author":"SY Shen","year":"2018","unstructured":"Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563:579\u201383.","journal-title":"Nature"},{"key":"1811_CR11","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.3390\/cancers12102993","volume":"12","author":"D Lam","year":"2020","unstructured":"Lam D, Clark S, Stirzaker C, Pidsley R. Advances in prognostic methylation biomarkers for prostate cancer. Cancers. 2020;12:2993. https:\/\/doi.org\/10.3390\/cancers12102993.","journal-title":"Cancers"},{"key":"1811_CR12","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3390\/cells9061362","volume":"9","author":"MT Bjerre","year":"2020","unstructured":"Bjerre MT, N\u00f8rgaard M, Larsen OH, Jensen S\u00d8, Strand SH, \u00d8stergren P, et al. Epigenetic analysis of circulating tumor DNA in localized and metastatic prostate cancer: evaluation of clinical biomarker potential. Cells. 2020;9:1362.","journal-title":"Cells"},{"key":"1811_CR13","doi-asserted-by":"publisher","first-page":"6467","DOI":"10.1038\/s41467-022-34012-2","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen S, Petricca J, Ye W, Guan J, Zeng Y, Cheng N, et al. The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. Nat Commun. 2022;13:6467.","journal-title":"Nat Commun"},{"key":"1811_CR14","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","volume":"32","author":"EA Klein","year":"2021","unstructured":"Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32:1167\u201377.","journal-title":"Ann Oncol"},{"key":"1811_CR15","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/cancers16030482","volume":"16","author":"T B\u00fcttner","year":"2024","unstructured":"B\u00fcttner T, Dietrich D, Zarbl R, Kl\u00fcmper N, Ellinger J, Krausewitz P, et al. Feasibility of monitoring response to metastatic prostate cancer treatment with a methylation-based circulating tumor DNA approach. Cancers (Basel). 2024;16:482. https:\/\/doi.org\/10.3390\/cancers16030482.","journal-title":"Cancers (Basel)"},{"key":"1811_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12943-021-01445-0","volume":"21","author":"T Dillinger","year":"2022","unstructured":"Dillinger T, Sheibani-Tezerji R, Pulverer W, Stelzer I, Hassler MR, Scheibelreiter J, et al. Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. Mol Cancer. 2022;21:7.","journal-title":"Mol Cancer"},{"key":"1811_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77:403\u201317.","journal-title":"Eur Urol"},{"key":"1811_CR18","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","volume":"48","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48:1200\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1811_CR19","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s12149-021-01610-x","volume":"35","author":"D Has Simsek","year":"2021","unstructured":"Has Simsek D, Kuyumcu S, Karadogan S, Oflas M, Isik EG, Ozkan ZG, et al. Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer? Ann Nucl Med. 2021;35:680\u201390.","journal-title":"Ann Nucl Med"},{"key":"1811_CR20","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s00259-024-06698-7","volume":"51","author":"K Kluge","year":"2024","unstructured":"Kluge K, Einspieler H, Haberl D, Spielvogel C, Amereller D, Egger G, et al. Comparison of discovery rates and prognostic utility of [68Ga]Ga-PSMA-11 PET\/CT and circulating tumor DNA in prostate cancer-a cross-sectional study. Eur J Nucl Med Mol Imaging. 2024;51:2833\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1811_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/978-1-4939-7481-8_21","volume":"1708","author":"G Beikircher","year":"2018","unstructured":"Beikircher G, Pulverer W, Hofner M, Noehammer C, Weinhaeusel A. Multiplexed and sensitive DNA methylation testing using methylation-sensitive restriction enzymes \u201cMSRE-qPCR.\u201d Methods Mol Biol. 2018;1708:407\u201324.","journal-title":"Methods Mol Biol"},{"key":"1811_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83:405\u201312.","journal-title":"Eur Urol"},{"key":"1811_CR23","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.19.02768","volume":"38","author":"SE Eggener","year":"2020","unstructured":"Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, et al. Molecular biomarkers in localized prostate cancer: ASCO guideline. J Clin Oncol. 2020;38:1474\u201394.","journal-title":"J Clin Oncol"},{"key":"1811_CR24","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41416-022-01881-9","volume":"127","author":"B Trujillo","year":"2022","unstructured":"Trujillo B, Wu A, Wetterskog D, Attard G. Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. Br J Cancer. 2022;127:1394\u2013402.","journal-title":"Br J Cancer"},{"key":"1811_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00176","volume":"3","author":"ST Hennigan","year":"2019","unstructured":"Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, et al. Low abundance of circulating tumor DNA in localized prostate cancer. JCO Precis Oncol. 2019;3:1\u201313. https:\/\/doi.org\/10.1200\/PO.19.00176.","journal-title":"JCO Precis Oncol"},{"key":"1811_CR26","doi-asserted-by":"publisher","first-page":"e000073","DOI":"10.1136\/bmjonc-2023-000073","volume":"3","author":"B Budnik","year":"2024","unstructured":"Budnik B, Amirkhani H, Forouzanfar MH, Afshin A. Novel proteomics-based plasma test for early detection of multiple cancers in the general population. BMJ Oncology. 2024;3:e000073.","journal-title":"BMJ Oncology"},{"key":"1811_CR27","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1634\/theoncologist.2010-0216","volume":"16","author":"R Aggarwal","year":"2011","unstructured":"Aggarwal R, Ryan CJ. Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist. 2011;16:264\u201375.","journal-title":"Oncologist"},{"key":"1811_CR28","first-page":"8","volume":"30","author":"C Parker","year":"2012","unstructured":"Parker C, Heinrich D, O\u2019Sullivan JM, Fossa SD, Chodacki A, Demkow T, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Orthod. 2012;30:8\u20138.","journal-title":"J Clin Orthod"},{"key":"1811_CR29","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","volume":"30","author":"WK Kelly","year":"2012","unstructured":"Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30:1534\u201340.","journal-title":"J Clin Oncol"},{"key":"1811_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med"},{"key":"1811_CR31","doi-asserted-by":"publisher","first-page":"7184","DOI":"10.1158\/0008-5472.CAN-06-4729","volume":"67","author":"X Wang","year":"2007","unstructured":"Wang X, Zheng M, Liu G, Xia W, McKeown-Longo PJ, Hung M-C, et al. Kr\u00fcppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res. 2007;67:7184\u201393.","journal-title":"Cancer Res"},{"key":"1811_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s12935-020-01508-0","volume":"20","author":"S Tian","year":"2020","unstructured":"Tian S, Lei Z, Gong Z, Sun Z, Xu D, Piao M. Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review. Cancer Cell Int. 2020;20:409.","journal-title":"Cancer Cell Int"},{"key":"1811_CR33","doi-asserted-by":"publisher","first-page":"8890","DOI":"10.1111\/jcmm.15581","volume":"24","author":"R Khayami","year":"2020","unstructured":"Khayami R, Hashemi SR, Kerachian MA. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential. J Cell Mol Med. 2020;24:8890\u2013902.","journal-title":"J Cell Mol Med"},{"key":"1811_CR34","first-page":"1220","volume":"14","author":"D Mukherjee","year":"2022","unstructured":"Mukherjee D, Hao J, Lu H, Lahiri SK, Yu L, Zhao J. KLF8 promotes invasive outgrowth of breast cancer by inducing filopodium-like protrusions via CXCR4. Am J Transl Res. 2022;14:1220\u201333.","journal-title":"Am J Transl Res"},{"key":"1811_CR35","doi-asserted-by":"publisher","first-page":"43720","DOI":"10.1074\/jbc.M112.418053","volume":"287","author":"H Lu","year":"2012","unstructured":"Lu H, Hu L, Li T, Lahiri S, Shen C, Wason MS, et al. A novel role of Kr\u00fcppel-like factor 8 in DNA repair in breast cancer cells. J Biol Chem. 2012;287:43720\u20139.","journal-title":"J Biol Chem"},{"key":"1811_CR36","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1093\/hmg\/ddy310","volume":"27","author":"BB Currall","year":"2018","unstructured":"Currall BB, Chen M, Sallari RC, Cotter M, Wong KE, Robertson NG, et al. Loss of LDAH associated with prostate cancer and hearing loss. Hum Mol Genet. 2018;27:4194\u2013203.","journal-title":"Hum Mol Genet"},{"key":"1811_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13148-019-0695-0","volume":"11","author":"AF Vega-Benedetti","year":"2019","unstructured":"Vega-Benedetti AF, Loi E, Moi L, Blois S, Fadda A, Antonelli M, et al. Clustered protocadherins methylation alterations in cancer. Clin Epigenetics. 2019;11:100.","journal-title":"Clin Epigenetics"},{"key":"1811_CR38","doi-asserted-by":"publisher","first-page":"101508","DOI":"10.1016\/j.tranon.2022.101508","volume":"25","author":"W-M Chang","year":"2022","unstructured":"Chang W-M, Li L-J, Chiu I-A, Lai T-C, Chang Y-C, Tsai H-F, et al. The aberrant cancer metabolic gene carbohydrate sulfotransferase 11 promotes non-small cell lung cancer cell metastasis via dysregulation of ceruloplasmin and intracellular iron balance. Transl Oncol. 2022;25:101508.","journal-title":"Transl Oncol"},{"key":"1811_CR39","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1002\/cam4.5186","volume":"12","author":"D-D Xiong","year":"2023","unstructured":"Xiong D-D, Li J-D, He R-Q, Li M-X, Pan Y-Q, He X-L, et al. Highly expressed carbohydrate sulfotransferase 11 correlates with unfavorable prognosis and immune evasion of hepatocellular carcinoma. Cancer Med. 2023;12:4938\u201350.","journal-title":"Cancer Med"},{"key":"1811_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41419-023-06398-4","volume":"15","author":"X Fu","year":"2024","unstructured":"Fu X, Zhang Q, Wang Z, Xu Y, Dong Q. CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1\u03b1. Cell Death Dis. 2024;15:21.","journal-title":"Cell Death Dis"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01811-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01811-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01811-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T14:42:14Z","timestamp":1740494534000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01811-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1811"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01811-5","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the Medical University of Vienna (ID: 1649\/2016). All participants signed informed consent for the sample collection, data analysis and result publication. For the retrospective part of the analysis, the need for informed consent was waived by the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Obtained for the prospective part, waived for the retrospective part.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No potential conflicts of interest relevant to this article exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}